Real-world data survival outcomes of first line immunotherapy with pembrolizumab in high expressers with stage IV non-small cell lung cancer.
- DOI
- 10.2478/raon-2026-0050
- Published
- 2026 Sep 1
- Container
- Radiology and oncology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.2478/raon-2026-0050,
title = {Real-world data survival outcomes of first line immunotherapy with pembrolizumab in high expressers with stage IV non-small cell lung cancer.},
author = {Stojsic V and Zaric B and Simurdic P and Kovacevic T and Bokan D and Malbasa JD and Sarcev T and Stojanovic G and Bursac D and Nikolin B},
year = {2026},
journal = {Radiology and oncology},
doi = {10.2478/raon-2026-0050},
url = {https://doi.org/10.2478/raon-2026-0050}
}RIS
TY - JOUR TI - Real-world data survival outcomes of first line immunotherapy with pembrolizumab in high expressers with stage IV non-small cell lung cancer. AU - Stojsic V AU - Zaric B AU - Simurdic P AU - Kovacevic T AU - Bokan D AU - Malbasa JD AU - Sarcev T AU - Stojanovic G AU - Bursac D AU - Nikolin B PY - 2026 JO - Radiology and oncology DO - 10.2478/raon-2026-0050 UR - https://doi.org/10.2478/raon-2026-0050 ER -
APA
V, S., B, Z., P, S., T, K., D, B., JD, M., T, S., G, S., D, B., & B, N. (2026). Real-world data survival outcomes of first line immunotherapy with pembrolizumab in high expressers with stage IV non-small cell lung cancer.. Radiology and oncology. https://doi.org/10.2478/raon-2026-0050
Source records
- pubmed · retrieved 2026-09-27T10:13:18.488Z